Skip to content

A randomized double-blind placebo-controlled multicenter clinical trial of Henggu Bone Injury Healing Agent in the treatment of long tubular bone fractures of the lower extremities (Qi stagnation and blood stasis syndrome)

A randomized double-blind placebo-controlled multicenter clinical trial of Henggu Bone Injury Healing Agent in the treatment of long tubular bone fractures of the lower extremities (Qi stagnation and blood stasis syndrome)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001347
Enrollment
Unknown
Registered
2025-07-06
Start date
2021-06-28
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture of the long tubular bone of the lower extremity

Interventions

Sponsors

Beijing Jishuitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Patients with a single lower limb long tubular bone fracture [femoral shaft fracture tibial fibular fracture (tibial shaft fracture)] and successfully underwent antegrade intramedullary needle internal fixation with closed reduction; 2) Consistent with the syndrome differentiation diagnosis of qi stagnation and blood stasis syndrome in traditional Chinese medicine; 3) Patients within 24 hours after surgery; 4) Male 18~60 years old (including 18 years old and 60 years old) female 18~50 years old (including 18 years old and 50 years old); 5) After the investigator explains the pros and cons of the trial in detail the patient is willing to participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) pathological fractures; 2) Patients with soft tissue infection at the surgical site; 3) Patients with pain caused by other diseases; 4) Patients with severe heart lung liver kidney and hematopoietic system diseases ALT and AST > twice the normal reference value Upper limit SCR > upper limit of normal reference value; 5) Patients with acute cerebrovascular disease diabetes mellitus with unsatisfactory blood sugar control grade III hypertension or unstable blood pressure control above high risk; 6) Pregnant lactating or intending to become pregnant including male subjects who have fertility intentions or fertility plans during the study period; 7) Patients with a history of psychiatric illness and glaucoma. 8) Use of other drugs that affect the evaluation of disease efficacy within 30 days before enrollment such as bisphosphonates calcitonin and stimulus Vegetarian drugs etc.; 9) Those who are known to be allergic to the ingredients of this drug or have allergic constitution; 10) According to the judgment of the investigator conditions that may affect the follow-up and compliance of the subjects after enrollment such as out-of-town disease unstable life inconvenient transportation and other situations that are easy to cause loss of follow-up; 11) Patients who have participated in other clinical trials within 1 month

Design outcomes

Primary

MeasureTime frame
VAS score for pain;Radiographic Union Score;

Secondary

MeasureTime frame
Frequency and dosage of analgesics;European five-dimensional health scale (eq-5d) score;Fracture Healing Time;Swelling time;Pain time;TCM score;Single symptom of TCM;

Countries

China

Contacts

Public ContactWu Xinbao

Beijing Jishuitan Hospital

zhangdandan@zyyjypj.cn15711415134

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026